Vertex Pharmaceuticals to Feature at Citi’s 2025 Global Healthcare Conference

The conference will be headlined by Charlie Wagner, the Chief Operating and Financial Officer, alongside David Altshuler, the Chief Scientific Officer. They are set to engage in a fireside chat at 9:00 a.m. ET, where they will likely delve into the company’s recent developments, ongoing research, and future direction.

For investors and stakeholders unable to attend in person, Vertex Pharmaceuticals will provide a live webcast of the discussion. This can be accessed via the company’s official website, specifically in the "Investors" section under the "News and Events" page. Following the event, a replay of the conference will also be archived on Vertex's website, ensuring that interested parties can catch up on the insights shared during the session.

Vertex Pharmaceuticals is recognized as a leader in the biotechnology industry, focusing on creating transformative medicines for serious diseases. The company has made significant strides in treating conditions such as cystic fibrosis, sickle cell disease, and transfusion-dependent beta thalassemia. Its commitment to advancing clinical and research programs reflects its dedication to understanding and addressing serious health conditions.

In addition to its approved therapies, Vertex boasts a robust clinical pipeline that includes investigational treatments across various modalities. These efforts address a wide range of serious diseases, including:

This diverse pipeline underscores Vertex's deep insights into causal human biology and its proactive approach to developing solutions for unmet medical needs.

Founded in 1989 and headquartered in Boston, Vertex Pharmaceuticals has established itself as a global powerhouse in biotechnology. The company maintains international headquarters in London, along with research and development sites and commercial offices across North America, Europe, Australia, Latin America, and the Middle East.

Vertex has also been recognized for its workplace culture, consistently ranking among the best employers in the industry. It has appeared on Science magazine's Top Employers list for 16 consecutive years and is listed among Fortune’s 100 Best Companies to Work For.

As Vertex Pharmaceuticals prepares for its appearance at Citi’s 2025 Global Healthcare Conference, stakeholders and industry observers are poised to gain valuable insights into the company’s strategic initiatives and future prospects. With a commitment to innovation and a focus on serious health conditions, Vertex continues to pave the way for advancements in the biotechnology landscape. For more information and updates, interested parties can visit Vertex's official website or follow the company on various social media platforms.